Drug Profile
Research programme: flibanserin - Monitoring Force
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator MONITORING FORCE GmbH
- Class Antidepressants; Anxiolytics; Benzimidazoles; Ketones; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Drug-induced dyskinesia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Drug-induced-dyskinesia in Germany (PO)
- 16 Nov 2009 Preclinical trials in Drug-induced dyskinesia in Germany (PO)